WASHINGTON (April 3, 2025) — The Association for Accessible Medicines today congratulated Dr. Mehmet Oz, M.D., on Senate confirmation to lead the Centers for Medicare & Medicaid Services.
“Congratulations to Dr. Oz on confirmation to lead CMS,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generic and Biosimilar medicines provide the greatest cost savings in health care for all patients, especially for Medicare and Medicaid. We are 90% of the medications dispensed in the U.S. and only 13% of the total drug spending. AAM and the Biosimilars Council look forward to working with Dr. Oz and his team at CMS to ensure lower-cost medicines are always available for America’s patients.”
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
